Is Screening for Heart Failure and Peripheral Artery Disease Warranted in Asymptomatic Adults With Diabetes? A Perspective on the 2025 American Diabetes Association “Standards of Care in Diabetes”
Authors' conclusion
While the intent to improve health care through screening is commendable, these recommendations are inadequately supported by the principles of screening and the published literature.
Study context
- Population
- Asymptomatic adults with diabetes
- Outcome
- Evaluation of 2025 ADA SOC screening recommendations for HF and PAD
Main finding
As reported in the abstract
- Recommendation to screen for HF using natriuretic peptide lacks robust evidence in several key areas
- NT-proBNP performs poorly as a screening test in asymptomatic adults
- Ambiguous treatment recommendations and insufficient evidence of improved outcomes with SGLT2i in adults with diabetes and stage B HF
- Costs of HF screening high and may not be economically justifiable
- Recommendation to screen for peripheral artery disease (PAD) in asymptomatic adults with diabetes not backed by rigorous scientific evidence
- Cited evidence combines ankle-brachial index (ABI) screening with other effective screening tests and has limited generalizability
- No guidance on interpreting ABI results or using them to direct treatment
Original publication
Is Screening for Heart Failure and Peripheral Artery Disease Warranted in Asymptomatic Adults With Diabetes? A Perspective on the 2025 American Diabetes Association “Standards of Care in Diabetes”. Diabetes Care. Published 12 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →